Charles Schwab Investment Management Inc. Sells 26,556 Shares of Perspective Therapeutics, Inc. (NYSE:CATX)

Charles Schwab Investment Management Inc. reduced its stake in shares of Perspective Therapeutics, Inc. (NYSE:CATX) by 6.1% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 406,966 shares of the company’s stock after selling 26,556 shares during the period. Charles Schwab Investment Management Inc. owned about 0.60% of Perspective Therapeutics worth $1,298,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently modified their holdings of CATX. State Street Corp raised its holdings in shares of Perspective Therapeutics by 119.6% in the third quarter. State Street Corp now owns 2,190,239 shares of the company’s stock valued at $29,240,000 after purchasing an additional 1,192,812 shares during the last quarter. Janus Henderson Group PLC grew its position in Perspective Therapeutics by 8.0% in the 3rd quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock worth $64,014,000 after purchasing an additional 355,685 shares in the last quarter. FMR LLC increased its stake in Perspective Therapeutics by 3,994.9% in the 3rd quarter. FMR LLC now owns 5,504,822 shares of the company’s stock valued at $73,489,000 after buying an additional 5,370,392 shares during the last quarter. BNP Paribas Financial Markets lifted its position in shares of Perspective Therapeutics by 1,302.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 47,565 shares of the company’s stock worth $635,000 after buying an additional 44,174 shares in the last quarter. Finally, Vontobel Holding Ltd. purchased a new position in shares of Perspective Therapeutics in the 4th quarter worth approximately $51,000. 54.66% of the stock is owned by hedge funds and other institutional investors.

Perspective Therapeutics Price Performance

NYSE CATX opened at $2.20 on Friday. The company’s 50 day moving average is $2.94 and its 200-day moving average is $6.36. Perspective Therapeutics, Inc. has a 12-month low of $2.19 and a 12-month high of $19.05.

Analyst Ratings Changes

A number of analysts recently commented on CATX shares. Lifesci Capital raised Perspective Therapeutics to a “strong-buy” rating in a research report on Thursday, March 6th. Wedbush reaffirmed an “outperform” rating and set a $11.00 target price on shares of Perspective Therapeutics in a research report on Wednesday. Cantor Fitzgerald raised shares of Perspective Therapeutics to a “strong-buy” rating in a report on Tuesday, March 4th. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Perspective Therapeutics in a report on Wednesday, March 19th. Finally, Royal Bank of Canada dropped their target price on shares of Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating on the stock in a research note on Thursday. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $14.44.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.